Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · IEX Real-Time Price · USD
32.04
-0.62 (-1.90%)
At close: Jul 19, 2024, 4:00 PM
32.09
+0.05 (0.16%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
HRMY Employees
Harmony Biosciences Holdings had 246 employees as of December 31, 2023. The number of employees increased by 46 or 23.00% compared to the previous year.
Employees
246
Change (1Y)
46
Growth (1Y)
23.00%
Revenue / Employee
$2,510,207
Profits / Employee
$559,764
Market Cap
1.82B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 246 | 46 | 23.00% |
Dec 31, 2022 | 200 | 20 | 11.11% |
Dec 31, 2021 | 180 | 30 | 20.00% |
Dec 31, 2020 | 150 | 0 | - |
Dec 31, 2019 | 150 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Zai Lab | 2,175 |
NeoGenomics | 2,100 |
Galapagos NV | 1,123 |
Veracyte | 815 |
RxSight | 374 |
Keros Therapeutics | 136 |
Neumora Therapeutics | 124 |
Verona Pharma | 79 |
HRMY News
- 26 days ago - HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) - PRNewsWire
- 4 weeks ago - HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY - PRNewsWire
- 6 weeks ago - HARMONY BIOSCIENCES PRESENTS POSITIVE DATA FOR PITOLISANT IN THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND FATIGUE IN MYOTONIC DYSTROPHY TYPE 1 - PRNewsWire
- 7 weeks ago - HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE - PRNewsWire
- 2 months ago - Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy - GlobeNewsWire
- 2 months ago - Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets - PRNewsWire
- 3 months ago - HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 - PRNewsWire
- 3 months ago - HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST - PRNewsWire